ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 732

Expansion Of IgA-Plasma Cells As a Sign For Ear-Nose-Throat-Involvment In Granulomatosis With Polyangiitis?

Bimba F. Hoyer1,2, Adriano Taddeo3, Qingyu Cheng2, Laleh Khodadadi2, Gerd Burmester2 and Falk Hiepe2, 1Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, 2Charité University Medicine, Department of Medicine/Rheumatology and Clinical Immunology and German Rheumatism Research Centre Berlin (DRFZ), Germany, Berlin, Germany, 3Deutsches Rheumaforschungszentrum, Berlin, Germany

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: B cells and Wegener's granulomatosis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: B cells are playing a major role in granulomatosis with polyangiitis (GPA, formarly known as Wegener’s disease). This is reflected by the presence of autoantibodies directed against neutrophil granular encymes ( ANCA) in a great majority of patients as well as in the success of B cell depleting therapies in GPA. Renal manifestations are  directly mediated by autoantibodies. Whether mucosal plasma cells play a role in ENT-involvment is yet unknown. IgA-ANCA can be found in about 30% of GPA patients ( Kelley et al). For a better understanding of the possible role of B cells in GPA we analyzed B cells subsets in the peripheral blood of patients and found major changes correlating with disease activity (BVAS).

Methods: 18 patients with GPA ( 11 with active disease, 7 in remission) were analyzed by flow cytometry and compared to 17 healthy donors. Stainings for CD19, 20, 27, IgD, IgA and MHCII were performed and analyzed by FlowJo-software. The study was approved by the Charité ethics committee and all patients signed informed consent. Statistical analysis was performed using GraphPadPrism.

Results: Marked differences ( p=0,0018) were found regarding the number and frequency of plasmablasts and plasma cells in patients with active disease ( 6,4 ± 5,06/µl) as compared to patients in remission ( 2,5 ± 1,6/µl) or healthy donors ( 2,3 ± 1,2/µl). In patients with GPA a significant higher number of the plasma cells produced IgA as compared to healthy controls ( p=0,0028).

The number of plasma cells as well as their frequency correlate with disease activity ( r= 0,9135, p<0,0001). Interestingly, no expansion of the double negative memory B cells that has been described in SLE could be seen. For naive B cells significant differences could be detected as well.

Conclusion: The number of plasma cells in active GPA is increased. This implies a central role of plasma cells in the pathogenesis of GPA. A high frequency of these plasma cells is producing IgA, which could play a role in ENT-involvement. Further studies including the analysis of ENT biopsies are needed to further understand their role in disease pathogenesis.


Disclosure:

B. F. Hoyer,
None;

A. Taddeo,
None;

Q. Cheng,
None;

L. Khodadadi,
None;

G. Burmester,
None;

F. Hiepe,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expansion-of-iga-plasma-cells-as-a-sign-for-ear-nose-throat-involvment-in-granulomatosis-with-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology